Beyond COVID-19: Risk and regulatory

Banking reform updater: Bank Recovery and Resolution Directive II

The EU banking package was adopted on May 20, 2019 by way of two directives (the Capital Requirements Directive V (CRD V) and the Bank Recovery and Resolution Directive II (BRRD II)) and two regulations (the Capital Requirements Regulation II (CRR II) and the Single Resolution Mechanism Regulation II (SRMR II)).

United Kingdom | Publication | April 15, 2020

Australia: Regulators and COVID-19: A changed enforcement focus does not excuse non-compliance

Australian regulators have acknowledged the tremendous challenges and disruptions facing Australian businesses as a result of COVID-19.

Australia | Publication | April 15, 2020

Quebec’s environmental protections relaxed during health emergency

Since the COVID 19 outbreak was declared a health emergency by the Quebec government on March 13, many measures have been taken, some of which have an impact on businesses’ environmental obligations.

Canada | Publication | April 15, 2020

Triaging, scoping and managing investigations: Making difficult decisions

We have set out below ten top tips on triaging, scoping and managing investigations.

Global | Publication | April 14, 2020

US: Maintaining enforcement risk vigilance while pursuing pharma opportunities in China

While many of us remain indoors and practice social distancing, business opportunities, especially in the global pharmaceutical market, continue to grow at a rapid pace.

United States | Publication | April 14, 2020

An ounce of prevention: Minimizing US antitrust risk when evaluating labor practices

US: An ounce of prevention: Minimizing antitrust risk when evaluating labor practices

COVID-19 has forced many companies to evaluate, and implement cuts to their workforces, reductions in pay, benefits, and hours, or both.

United States | Publication | April 09, 2020

Cooperation amid COVID-19: Medical supply collaboration won’t face US antitrust scrutiny

US: Cooperation amid COVID-19: Medical supply collaboration won’t face antitrust scrutiny

The US DOJ announced in a business review letter its intent not to challenge an ongoing collaboration between numerous healthcare companies

United States | Publication | April 09, 2020

Global: Credit for compliance: Achieving the benefits of a robust antitrust compliance program

COVID-19 (coronavirus) is naturally the focus of everyone’s attention currently given the unprecedented scale of the crisis.

Global | Publication | April 08, 2020

Fraud prevention: An essential function during the pandemic

The fraud triangle is a well-known tool in understanding fraud. The three sides – opportunity, incentive, and rationalization – offer an explanation to a person’s decision to commit fraud.

Canada | Publication | April 06, 2020